Abstract: The present disclosure relates to a neutralizing antibody specific to human denatured CRP that can be used for a medicine such as an anti-inflammatory agent. The present disclosure also relates to various inventions relating to the neutralizing antibody specific to human denatured CRP.

Abstract: The present disclosure relates to a method useful in the determination of adult Still's disease (ASD). More specifically, the present disclosure relates to (I) a method for testing adult Still's disease, including (1) measuring a denatured CRP concentration in a blood sample collected from a subject; and (2) comparing the measured denatured CRP concentration and/or an index value based on the denatured CRP concentration with a reference value; (II) a denatured CRP-specific antibody; and (III) a kit for testing adult Still's disease.

Abstract: An analysis apparatus according to an embodiment includes an extraction unit, a calculation unit, and an evaluation unit. The extraction unit extracts a detection value in a tumor region, a blood region, and a muscle region from a nuclear medicine image of a subject administered with a drug containing a radiolabeled anticancer drug that works by accumulating in a tumor. The calculation unit calculates a first comparison value that is a comparison result between the detection value in the blood region and the detection value in the tumor region, and a second comparison value that is a comparison result between the detection value in the muscle region and the detection value in the tumor region. The evaluation unit evaluates an accumulation of the drug in the tumor, based on the first comparison value and the second comparison value calculated by the calculation unit.

Abstract: An analysis apparatus according to an embodiment includes an extraction unit, a calculation unit, and an evaluation unit. The extraction unit extracts a detection value in a tumor region, a blood region, and a muscle region from a nuclear medicine image of a subject administered with a drug containing a radiolabeled anticancer drug that works by accumulating in a tumor. The calculation unit calculates a first comparison value that is a comparison result between the detection value in the blood region and the detection value in the tumor region, and a second comparison value that is a comparison result between the detection value in the muscle region and the detection value in the tumor region. The evaluation unit evaluates an accumulation of the drug in the tumor, based on the first comparison value and the second comparison value calculated by the calculation unit.

Abstract: This method provides a method for delivering shRNA targeting TS in vivo. In addition, the following is provided: an antitumor agent, which comprises short hairpin RNA (shRNA) capable of inhibiting expression of thymidylate synthase by RNAi action and a PEG-modified cationic liposome, wherein the shRNA is bound to the surface of the PEG-modified cationic liposome and has an overhang comprising at least two nucleotides at the 3? end.

Abstract: This invention provides a novel RNAi molecule that can significantly potentiate antitumor effects of a 5-FU antitumor agent. The RNAi molecule comprises the nucleotide sequence shown in SEQ ID NO: 2. The invention also provides an antitumor agent comprising such RNAi molecule and a 5-FU antitumor agent.

Abstract: This method provides a method for delivering shRNA targeting TS in vivo. In addition, the following is provided: an antitumor agent, which comprises short hairpin RNA (shRNA) capable of inhibiting expression of thymidylate synthase by RNAi action and a PEG-modified cationic liposome, wherein the shRNA is bound to the surface of the PEG-modified cationic liposome and has an overhang comprising at least two nucleotides at the 3? end.

Abstract: This method provides a method for delivering shRNA targeting TS in vivo. In addition, the following is provided: an antitumor agent, which comprises short hairpin RNA (shRNA) capable of inhibiting expression of thymidylate synthase by RNAi action and a PEG-modified cationic liposome, wherein the shRNA is bound to the surface of the PEG-modified cationic liposome and has an overhang comprising at least two nucleotides at the 3? end.

Abstract: This invention provides a novel RNAi molecule that can significantly potentiate antitumor effects of a 5-FU antitumor agent. The RNAi molecule comprises the nucleotide sequence shown in SEQ ID NO: 2. The invention also provides an antitumor agent comprising such RNAi molecule and a 5-FU antitumor agent.

Abstract: A lesion portion determining method of an infrared observing system includes at least an observing apparatus. The observing apparatus includes a light source device which radiates light of a first wavelength band including a wavelength of 805 nm and light of a second wavelength band including a wavelength longer than 805 nm, an image pick-up device which picks up an image of the first wavelength band and an image of the second wavelength band of an object irradiated by the light radiated from the light source device, display means which displays, as any color component of red, green, and blue, the image of the first wavelength band and the image of the second wavelength band that are picked-up by the image pick-up device. The lesion portion determining method includes a step of administering an infrared absorbing pigment to a patient, and a step of observing a visible range of the infrared absorbing pigment by the observing apparatus.

Abstract: A lesion portion determining method of an infrared observing system includes at least an observing apparatus. The observing apparatus includes a light source device which radiates light of a first wavelength band including a wavelength of 805 nm and light of a second wavelength band including a wavelength longer than 805 nm, an image pick-up device which picks up an image of the first wavelength band and an image of the second wavelength band of an object irradiated by the light radiated from the light source device, display means which displays, as any color component of red, green, and blue, the image of the first wavelength band and the image of the second wavelength band that are picked-up by the image pick-up device. The lesion portion determining method includes a step of administering an infrared absorbing pigment to a patient, and a step of observing a visible range of the infrared absorbing pigment by the observing apparatus.